Market Overview

UPDATE: Barclays Begins Coverage on Cerner and Advisory Board

Share:
Related CERN
Morning Market Losers
Benzinga's Top Downgrades
Cerner & Hospira to Enhance I.V.-EMR Technology Integration (Zacks)
Related ABCO
Baird Says 'Buy The Dip' In The Advisory Board Co, Upgrades To Outperform
Benzinga's Top Initiations

Barclays Wednesday reports includes a note from analyst Eric Percher for coverage initiation on Cerner (NASDAQ: CERN) and The Advisory Board Company (NASDAQ: ABCO) with an Overweight rating for each company. Price target of $79.

Percher notes, "Given our findings that the transition to value-based reimbursement and implementation of population health tools on a large scale will be at least a five- to seven-year journey, we favor companies that either provide services which will enable the journey itself or have demonstrated opportunities to drive growth outside of population health offerings. We believe no company is better positioned to advise hospital leadership than Advisory Board and Cerner's diversified growth strategy should drive double-digit growth even absent meaningful population health contributions."

ABCO closed Tuesday at $66.79 and opened Wednesday morning at $67. CERN closed previous session at $61.86 and opened at $61.94.

Latest Ratings for CERN

DateFirmActionFromTo
Aug 2015Stifel NicolausDowngradesHoldSell
Aug 2015RBC CapitalDowngradesOutperformSector Perform
Jun 2015OppenheimerInitiates Coverage onOutperform

View More Analyst Ratings for CERN
View the Latest Analyst Ratings

Posted-In: BarclaysPrice Target Initiation Analyst Ratings

 

Related Articles (ABCO + CERN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters